Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.350-0.410 for the period, compared to the consensus EPS estimate of 0.360. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $398.9 million.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Craig Hallum dropped their price target on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Stephens lowered their target price on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. BMO Capital Markets reduced their price target on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Tuesday, May 12th. Finally, Morgan Stanley lowered their price objective on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.85.

Certara Stock Performance

Shares of Certara stock opened at $6.36 on Tuesday. The business has a 50-day moving average price of $5.58 and a two-hundred day moving average price of $6.90. Certara has a 1-year low of $4.45 and a 1-year high of $13.88. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The company has a market cap of $989.39 million, a P/E ratio of -63.60 and a beta of 1.49.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business’s revenue was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, analysts anticipate that Certara will post 0.24 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Corient Private Wealth LLC bought a new stake in shares of Certara during the fourth quarter worth about $100,000. T. Rowe Price Investment Management Inc. grew its position in shares of Certara by 580,097.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock valued at $7,310,000 after acquiring an additional 829,540 shares during the period. nVerses Capital LLC bought a new position in shares of Certara during the 4th quarter worth $184,000. Toronto Dominion Bank increased its holdings in Certara by 186.9% in the 4th quarter. Toronto Dominion Bank now owns 83,939 shares of the company’s stock worth $739,000 after acquiring an additional 54,677 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in shares of Certara during the 4th quarter valued at approximately $256,000. 73.96% of the stock is owned by institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.